<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110110</url>
  </required_header>
  <id_info>
    <org_study_id>1000005587</org_study_id>
    <secondary_id>HFSC-OCRN-RB-2003</secondary_id>
    <secondary_id>CDR0000422340</secondary_id>
    <nct_id>NCT00110110</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma</brief_title>
  <official_title>Multicenter Phase II Study for International Intraocular Retinoblastoma Classification Groups B, C &amp; D Tumors Treated With Carboplatin-Etoposide-Vincristine-Cyclosporine-Focal Therapy Multimodality Protocol (OCRN Multicenter RB 2003)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terry Fox Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin, etoposide, and vincristine, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Sometimes when chemotherapy is given, it does not stop the&#xD;
      growth of tumor cells. The tumor is said to be resistant to chemotherapy. Giving cyclosporine&#xD;
      together with chemotherapy may reduce drug resistance and allow the tumor cells to be killed.&#xD;
      Cryotherapy kills tumor cells by freezing them. Laser therapy uses light to kill tumor cells.&#xD;
      Giving combination chemotherapy together with cyclosporine followed by cryotherapy and/or&#xD;
      laser therapy may be an effective treatment for retinoblastoma.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with cyclosporine followed by cryotherapy and/or laser therapy works in treating patients&#xD;
      with newly diagnosed retinoblastoma in both eyes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the efficacy of neoadjuvant high-dose carboplatin and etoposide, vincristine,&#xD;
           and cyclosporine (CSA) followed by ophthalmic focal therapy comprising cryotherapy&#xD;
           and/or laser therapy to historical world data of chemotherapy treatment without CSA, in&#xD;
           terms of increasing the proportion of eyes that remain relapse free and do not require&#xD;
           external beam radiotherapy and/or enucleation, in patients with newly diagnosed Group B,&#xD;
           C, or D bilateral intraocular retinoblastoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive high-dose carboplatin IV over 30 minutes on day 1; vincristine IV over 5&#xD;
      minutes and high-dose etoposide IV over 25 minutes on day 2; cyclosporine IV over 1 hour&#xD;
      before chemotherapy and then over 2 hours after chemotherapy on days 1 and 2, and filgrastim&#xD;
      (G-CSF) subcutaneously once daily beginning on day 3 and continuing until day 16 or until&#xD;
      blood counts recover. Treatment repeats every 21 days for a total of 3 courses for patients&#xD;
      with Group B disease and a total of 6 courses for patients with Group C or D disease.&#xD;
&#xD;
      Patients undergo eye examination under anesthesia (EUA) at initial staging and then before&#xD;
      each course of chemotherapy. Patients with small peripheral tumors in eyes without retinal&#xD;
      detachment undergo minimal focal therapy (mainly cryotherapy) during EUA at initial staging&#xD;
      and then after chemotherapy courses 1 and 2. At EUA after the third and subsequent courses of&#xD;
      chemotherapy, patients with tumors that have sufficiently reduced in size undergo additional&#xD;
      cryotherapy or laser therapy. After completion of chemotherapy, patients with any suspicious,&#xD;
      active, or reactivated tumor undergo additional cryotherapy and/or laser therapy during EUA&#xD;
      approximately every 4-8 weeks (or at longer intervals) for up to 5 years (as needed).&#xD;
&#xD;
      After completion of study chemotherapy, patients are followed every 3 months for 2 years,&#xD;
      every 6 months for 2 years, and then annually for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 71 patients will be accrued for this study within 2.4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2004</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">April 20, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing efficacy of study treatment with historic world data, in terms of increasing the proportion of eyes that remains relapse-free while avoiding external beam radiation and/or enucleation</measure>
    <time_frame>5 year follow-up per patient</time_frame>
    <description>Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity during treatment</measure>
    <time_frame>5 year follow-up per patient</time_frame>
    <description>Toxicity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>CEV Chemo + Cyclosporine &amp; Focal Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systemic carboplatin (28 mg/kg/dose), etoposide (12 mg/kg/dose) and vincristine sulfate (0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated) chemotherapy given with cyclosporin A (33 mg/kg/dose). Following 4-6 cycles CEV chemotherapy (depending on tumor stage) given every 3 weeks, focal laser therapy and/or cryosurgery are applied for tumor consolidation. Filgrastim is given after each chemotherapy cycle to prevent severe neutropenia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given after chemo cycle for 7 days or until neutrophil counts return to normal.</description>
    <arm_group_label>CEV Chemo + Cyclosporine &amp; Focal Therapy</arm_group_label>
    <other_name>granulocyte colony-stimulating factor (G-CSF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given at 28 mg/kg/dose.</description>
    <arm_group_label>CEV Chemo + Cyclosporine &amp; Focal Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given at 33 mg/kg/dose</description>
    <arm_group_label>CEV Chemo + Cyclosporine &amp; Focal Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given at 12 mg/kg/dose</description>
    <arm_group_label>CEV Chemo + Cyclosporine &amp; Focal Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given at 0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated</description>
    <arm_group_label>CEV Chemo + Cyclosporine &amp; Focal Therapy</arm_group_label>
    <other_name>vincristine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cryosurgery</intervention_name>
    <description>Local application of extreme cold to destroy residual tumor.</description>
    <arm_group_label>CEV Chemo + Cyclosporine &amp; Focal Therapy</arm_group_label>
    <other_name>cryotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laser therapy</intervention_name>
    <description>Local and precise application of laser beams to destroy residual tumor.</description>
    <arm_group_label>CEV Chemo + Cyclosporine &amp; Focal Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        &gt;&gt;INCLUSION CRITERIA&lt;&lt;&#xD;
&#xD;
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Clinical diagnosis of bilateral intraocular retinoblastoma (RB)&#xD;
&#xD;
               -  International Intraocular Retinoblastoma Classification (IIRC) Group B, C, or D&#xD;
                  disease in 1 or both eyes&#xD;
&#xD;
               -  IIRC Group E disease in 1 eye allowed provided the eye was enucleated at&#xD;
                  diagnosis AND there is no extraocular RB in the enucleated eye by histologic&#xD;
                  confirmation AND there is IIRC Group B, C, or D disease in the remaining eye&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 30 days&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Conjugated and unconjugated bilirubin &lt; 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) ≥ 100 mL/min* NOTE: *A 4-hour IV hydration is allowed&#xD;
             if GFR is low due to poor hydration or transient dehydration&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Meets 1 of the following auditory criteria:&#xD;
&#xD;
               -  Normal audiogram&#xD;
&#xD;
               -  At least normal responses to speech by audiogram&#xD;
&#xD;
               -  Documentation of hearing by acoustic emission test&#xD;
&#xD;
               -  Recording of evoked potentials by auditory brain stem response&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
             &gt;&gt;EXCLUSION CRITERIA&lt;&lt;&#xD;
&#xD;
          -  IIRC Group A disease in 1 or both eyes&#xD;
&#xD;
          -  unilateral RB&#xD;
&#xD;
          -  extraocular or metastatic RB&#xD;
&#xD;
          -  younger than 30 days&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) &lt; 100 mL/min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda L Gallie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elise Heon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen SL Chan, MD, BS</last_name>
    <role>Study Chair</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's and Women's Hospital of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital at McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Santiago</city>
        <zip>8500000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sankara Nethralaya Super Specialty Clinic</name>
      <address>
        <city>Chennai</city>
        <zip>600 006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kandang Kerbau Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>India</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Helen Chan</investigator_full_name>
    <investigator_title>Oncologist</investigator_title>
  </responsible_party>
  <keyword>intraocular retinoblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

